Kalcij/vitamin D3 Lek 1000 mg/880 i.e. žvečljive tablete Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

kalcij/vitamin d3 lek 1000 mg/880 i.e. žvečljive tablete

holekalciferol (vitamin d3); kalcij - žvečljiva tableta - holekalciferol (vitamin d3) 880 i.e. / 1 tableta  kalcij1000 i.e. / 1 tableta; kalcij 1000 i.e. / 1 tableta - kalcij, kombinacije z vitaminom d in/ali drugimi učinkovinami

GATTART 680 mg/80 mg žvečljive tablete Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

gattart 680 mg/80 mg žvečljive tablete

kalcijev karbonat; magnezijev subkarbonat, težki - žvečljiva tableta - kalcijev karbonat 680 mg / 1 tableta  magnezijev subkarbonat, težki80 mg / 1 tableta; magnezijev subkarbonat, težki 80 mg / 1 tableta - običajne kombinacije soli

GATTART 680 mg/80 mg žvečljive tablete Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

gattart 680 mg/80 mg žvečljive tablete

kalcijev karbonat; magnezijev subkarbonat, težki - žvečljiva tableta - kalcijev karbonat 680 mg / 1 tableta  magnezijev subkarbonat, težki80 mg / 1 tableta; magnezijev subkarbonat, težki 80 mg / 1 tableta - običajne kombinacije soli

Imfinzi Evropska unija - slovenščina - EMA (European Medicines Agency)

imfinzi

astrazeneca ab - durvalumab - karcinom, pljučni pljuč - antineoplastična sredstva - non-small cell lung cancer (nsclc)imfinzi as monotherapy is indicated for the treatment of locally advanced, unresectable non small cell lung cancer (nsclc) in adults whose tumours express pd-l1 on ≥ 1% of tumour cells and whose disease has not progressed following platinum based chemoradiation therapy (see section 5. imfinzi in combination with tremelimumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic nsclc with no sensitising egfr mutations or alk positive mutations. small cell lung cancer (sclc)imfinzi in combination with etoposide and either carboplatin or cisplatin is indicated for the first-line treatment of adults with extensive-stage small cell lung cancer (es-sclc). biliary tract cancer (btc)imfinzi in combination with gemcitabine and cisplatin is indicated for the first line treatment of adults with unresectable or metastatic biliary tract cancer (btc). hepatocellular carcinoma (hcc)imfinzi in combination with tremelimumab is indicated for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma (hcc).

Libtayo Evropska unija - slovenščina - EMA (European Medicines Agency)

libtayo

regeneron ireland designated activity company (dac) - cemiplimab - karcinoma, squamous cell - antineoplastična sredstva - cutaneous squamous cell carcinomalibtayo as monotherapy is indicated for the treatment of adult patients with metastatic or locally advanced cutaneous squamous cell carcinoma (mcscc or lacscc) who are not candidates for curative surgery or curative radiation. basal cell carcinomalibtayo as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic basal cell carcinoma (labcc or mbcc) who have progressed on or are intolerant to a hedgehog pathway inhibitor (hhi). non-small cell lung cancerlibtayo as monotherapy is indicated for the first-line treatment of adult patients with non-small cell lung cancer (nsclc) expressing pd-l1 (in ≥ 50% tumour cells), with no egfr, alk or ros1 aberrations, who have:locally advanced nsclc who are not candidates for definitive chemoradiation, ormetastatic nsclc. libtayo in combination with platinum‐based chemotherapy is indicated for the first‐line treatment of adult patients with nsclc expressing pd-l1 (in ≥ 1% of tumour cells), with no egfr, alk or ros1 aberrations, who have:locally advanced nsclc who are not candidates for definitive chemoradiation, ormetastatic nsclc. cervical cancerlibtayo as monotherapy is indicated for the treatment of adult patients with recurrent or metastatic cervical cancer and disease progression on or after platinum-based chemotherapy.

Strattera 100 mg trde kapsule Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

strattera 100 mg trde kapsule

eli lilly farmacevtska druŽba, d.o.o. - atomoksetin - kapsula, trda - atomoksetin 100 mg / 1 kapsula - atomoksetin

Strattera 100 mg trde kapsule Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

strattera 100 mg trde kapsule

eli lilly farmacevtska druŽba, d.o.o. - atomoksetin - kapsula, trda - atomoksetin 100 mg / 1 kapsula - atomoksetin

Strattera 80 mg trde kapsule Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

strattera 80 mg trde kapsule

eli lilly farmacevtska druŽba, d.o.o. - atomoksetin - kapsula, trda - atomoksetin 80 mg / 1 kapsula - atomoksetin

Strattera 80 mg trde kapsule Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

strattera 80 mg trde kapsule

eli lilly farmacevtska druŽba, d.o.o. - atomoksetin - kapsula, trda - atomoksetin 80 mg / 1 kapsula - atomoksetin

Strattera 4 mg/ml peroralna raztopina Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

strattera 4 mg/ml peroralna raztopina

eli lilly farmacevtska druŽba, d.o.o. - atomoksetin - peroralna raztopina - atomoksetin 4 mg / 1 ml - atomoksetin